HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma.
Context.--ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 140; no. 12; pp. 1345 - 1364 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | algorithm pictorial tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Dec2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120019785&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 120019785 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Dec2016 vid: 140 iid: 12 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 120019785 120019785 120019785 10.5858/arpa.2016-0331-CP 120019785 ppf: 1345 ppct: 19 formats: fmt: @attributes: type: P tig: atl: HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. aug: au: Bartley, Angela N. Washington, Mary Kay Ventura, Christina B. Ismaila, Nofisat Colasacco, Carol Benson III, Al B. Carrato, Alfredo Gulley, Margaret L. Jain, Dhanpat Kakar, Sanjay Mackay, Helen J. Streutker, Catherine Tang, Laura Troxell, Megan Ajani, Jaffer A. affil: Department of Pathology, St. Joseph Mercy Hospital, Ann Arbor, Michigan sug: subj: HER-2-neu Oncogene Decision Making, Clinical Adenocarcinoma Intestinal Neoplasms Practice Guidelines Algorithms College of American Pathologists Policy Making Conflict of Interest ab: Context.--ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. Objectives.--To establish an evidence-based guideline for HER2 testing in patients with GEA, to formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. Design.--The College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology convened an expert panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. Results.--The panel is proposing 11 recommendations with strong agreement from the open-comment participants. Recommendations.--The panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and a HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. Conclusions.--This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results. pubtype: Academic Journal doctype: algorithm pictorial tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|